

Application No.: 10/705,745
Attorney Docket No: 0208us520
Preliminary Amendment dated July 15, 2004
Page 8 of 9

BEST AVAILABLE COPY**REMARKS****Amendments to the Specification**

The specification is amended to update the Cross-Reference to Related Applications section to reflect that this application is a division of USSN 09/760,008. A Supplemental Application Data Sheet is also provided herein reflecting that change.

Status of the Claims

Claims 1-33 are canceled herein without prejudice to subsequent renewal or filing in one or more continuation and/or divisional applications. New claims 34-67 added herein.

The new claims find support in the originally-filed claims and throughout the specification, and introduce no new matter. Support for "differs from the hG-CSF sequence shown in SEQ ID NO:1 in no more than 15 amino acid residues" in claim 34 can be found at least at page 15 line 24-page 16 line 7. Support for claim 38 is found, for example, at least at pages 75 line 9- page 77 line 22. Support for claim 41 is found, for example, at least at page 15 line 31-page 16 line 7. Support for claim 44 is found, for example, at least at page 6 line 31-page 8 line 5, page 14 lines 28-31, and page 17 lines 5-19. Support for claim 45 is found, for example, at least at page 75 lines 6-7. Support for claim 46 is found, for example, at least at page 70 lines 16-27. Support for claim 55 is found, for example, at least in original claim 33. Support for claim 56 is found, for example, at least at page 47 lines 7-12. Support for claim 57 is found, for example, at least at page 27 line 33-page 28 line 10, and page 37 lines 20-26. Support for claims 58-65 is found, for example, at least at page 27 line 33-page 28 line 10, page 32 lines 19-25, and page 43 line 19-page 44 line 20.

Claims 33-54 are drawn to a polypeptide or to a conjugate comprising the polypeptide, all which comprise the substitution Q70K. Claims 55-67 are drawn to methods which depend from or otherwise incorporate all of the limitations of the product (polypeptide/conjugate) claims. In the event any product claims are found allowable, Applicants request examination of the method claims in this application, pursuant to 35 USC §121 and MPEP §821.04.

Application No.: 10/705,745
Attorney Docket No: 0208us520
Preliminary Amendment dated July 15, 2004
Page 9 of 9

BEST AVAILABLE COPY

CONCLUSION

If an additional fee is required for entry of this paper, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990.

If a telephone conference would expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (650) 298-5452.

Respectfully submitted,



Joanne R. Petithory, Ph.D.
Reg. No. 42,995

July 15 2004

Maxygen, Inc.
Intellectual Property Dept.
515 Galveston Drive
Redwood City, CA 94063
Customer Number 30560

Phone: (650) 298-5452 (direct)
(650) 298-5300 (main)
Fax: (650) 298-5446